Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting

Padmanee Sharma, Chrysoula Liakou, Ashish Kamat, Hong Chen, Derek Ng Tang, Jingjing Sun, Patricia Troncoso and Christopher Logothetis
Padmanee Sharma
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chrysoula Liakou
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashish Kamat
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Chen
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek Ng Tang
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingjing Sun
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Troncoso
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Logothetis
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

CTLA4 blockade is an active immunotherapeutic strategy that is currently in clinical trials with cancer patients. Anti-CTLA4 therapy has led to measurable decreases in tumor size in patients with metastatic disease, including durable complete responses in some patients. While greater than 1000 cancer patients have been treated with anti-CTLA4 antibody therapy, there has been no hallmark immunological change demonstrated to be associated with drug administration or clinical benefit. Here we present data from a neoadjuvant anti-CTLA4 clinical trial in bladder cancer patients demonstrating immunological changes that are consistent in both the circulating blood and tumor microenvironment. Furthermore, our data demonstrates an increased ratio of effector to regulatory T cells. This is the first report in human patients that anti-CTLA4 therapy favorably shifts the ratio of effector to regulatory T cells, which may be a potential marker for clinical benefit.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Padmanee Sharma
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting
Padmanee Sharma, Chrysoula Liakou, Ashish Kamat, Hong Chen, Derek Ng Tang, Jingjing Sun, Patricia Troncoso and Christopher Logothetis
Cancer Immun January 1 2008 (8) (Suppl 1) 11;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting
Padmanee Sharma, Chrysoula Liakou, Ashish Kamat, Hong Chen, Derek Ng Tang, Jingjing Sun, Patricia Troncoso and Christopher Logothetis
Cancer Immun January 1 2008 (8) (Suppl 1) 11;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The collaboration for AIDS vaccine discovery: A model for accelerating research
  • Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement